Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 17, 2020 | Post-IPO Equity | $42.30M | 1 | — | — | Detail |
Jul 23, 2019 | Series C | — | 1 | — | — | Detail |
Jan 7, 2019 | Series B | — | 1 | — | — | Detail |
Apr 11, 2017 | Series A | $32M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Maven Investment Partners US | — | Post-IPO Equity |
Polaris Founders Capital | — | Series C |
Emigrant Capital | — | Series B |